There is no proven safe and effective treatment for tardive dyskinesia which remains a major concern in psychiatry. At present, conventional antipsychotic drugs have all been associated with risk of tardive dyskinesia development. The major question now is whether or not the new 'novel' or 'atypical' antipsychotic will produce significantly less tardive dyskinesia than conventional drugs. This question is of enormous clinical economic and heuristic importance and will not be answered in a timely fashion unless appropriate, focused methodology is brought to bear. The present proposal will prospectively determine the incidence of tardive dyskinesia in a sample of high risk patients (individuals over the age of 55) being treated with antipsychotic drugs for the first time under routine clinical care. Patients receiving either of two new-generation antipsychotic drugs, risperidone or olanzapine, will be included and followed longitudinally. Two hundred sixty patients starting on each drug will be included. The incidence of new cases of TD will be contrasted with data from a previous study of 261 patients treated with conventional antipsychotics and followed prospectively from the initiation of treatment. This strategy will provide a rapid and cost-effective answer to a critical question.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH032369-21
Application #
6185926
Study Section
Clinical Psychopathology Review Committee (CPP)
Program Officer
Olin, Jason T
Project Start
1979-03-01
Project End
2002-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
21
Fiscal Year
2000
Total Cost
$240,831
Indirect Cost
Name
Long Island Jewish Medical Center
Department
Type
DUNS #
City
New Hyde Park
State
NY
Country
United States
Zip Code
11040
Woerner, Margaret G; Correll, Christoph U; Alvir, Jose Ma J et al. (2011) Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 36:1738-46
Correll, Christoph U; Leucht, Stefan; Kane, John M (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414-25
Kane, J M (1999) Management strategies for the treatment of schizophrenia. J Clin Psychiatry 60 Suppl 12:13-7
Kane, J M (1999) Tardive dyskinesia in affective disorders. J Clin Psychiatry 60 Suppl 5:43-7;discussion 48-9
Kane, J M (1999) Pharmacologic treatment of schizophrenia. Biol Psychiatry 46:1396-408
Miller, C H; Mohr, F; Umbricht, D et al. (1998) The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 59:69-75
Woerner, M G; Alvir, J M; Saltz, B L et al. (1998) Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155:1521-8
Chakos, M H; Alvir, J M; Woerner, M G et al. (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 53:313-9
Umbricht, D; Kane, J M (1996) Medical complications of new antipsychotic drugs. Schizophr Bull 22:475-83
Chakos, M H; Lieberman, J A; Alvir, J et al. (1995) Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 345:456-7

Showing the most recent 10 out of 26 publications